# A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy

> **NCT04151563** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Bristol-Myers Squibb**

## Conditions studied

- Carcinoma, Non-small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** nivolumab
- **BIOLOGICAL:** ipilimumab
- **DRUG:** cabozantinib
- **BIOLOGICAL:** docetaxel
- **BIOLOGICAL:** ramucirumab
- **DRUG:** lucitanib

## Key facts

- **NCT ID:** NCT04151563
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-04-15
- **Primary completion:** 2023-12-17
- **Final completion:** 2026-05-13
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Business objectives have changed
- **Last updated:** 2023-12-19

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04151563

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04151563, "A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT04151563. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*